Published in Obesity and Diabetes Week, May 30th, 2005
These new preliminary observations from the Macugen phase 2 DME trial were presented at the 2005 Association for Research in Vision and Ophthalmology annual meeting. Macugen is indicated in the United States for the treatment of neovascular age-related macular degeneration (neovascular AMD) and is not approved for the treatment of DME.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.